CYP3A4 and breast cancer: In addition to evidence of deregulated drug metabolism through augmented activity of the DOX-metabolizer CYP3A4, other important pathways, previously reported to be involved in tumor progression and chemotherapy resistance, were also found to be deregulated in the first stages of acquisition of DOX-resistance in BC cells.